Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning

Novartis faced increased scrutiny over its dealmaking strategy after clinical setbacks weakened confidence in its pipeline and acquisition approach. The article fragment does not provide specific trial results, financial figures, or share-price moves, but the developments represent a modest negative for investor sentiment.